Compare GLND & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLND | ANIX |
|---|---|---|
| Founded | N/A | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.0M | 114.0M |
| IPO Year | 2026 | 2013 |
| Metric | GLND | ANIX |
|---|---|---|
| Price | $3.90 | $2.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | ★ 25.6M | 297.3K |
| Earning Date | 11-18-2026 | 09-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $210,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.09 | $2.32 |
| 52 Week High | $12.80 | $5.46 |
| Indicator | GLND | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 58.64 | 36.52 |
| Support Level | $2.60 | $2.62 |
| Resistance Level | $6.69 | $3.09 |
| Average True Range (ATR) | 0.82 | 0.15 |
| MACD | -0.14 | -0.00 |
| Stochastic Oscillator | 36.47 | 2.08 |
Greenland Energy Co is a Texas energy resources company focused on unlocking Greenland's vast hydrocarbon potential through the application of modern exploration technologies. It holds exclusive licenses to over 2-million acre area in the Jameson Land Basin, where its licenses cover the majority of the basin. The business model for the company is based on exploration and resource development in the frontier basins of Greenland. The company's primary focus is drilling the first wells on the project to conduct the necessary exploration, appraisal and evaluation.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.